Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled trial

Psychopharmacology

Volumn 213, Issue 4, 2011, Pages 809-815

  Akhondzadeh, Shahin ^a   Ghayyoumi, Raofeh ^a   Rezaei, Farzin ^b   Salehi, Bahman ^c   Modabbernia, Amir Hossein ^a   Maroufi, Azad ^b   Esfandiari, Gholam Reza ^b   Naderi, Mehrangiz ^c   Ghebleh, Fariba ^c   Tabrizi, Mina ^d   Rezazadeh, Shams Ali ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e Institute of Medicinal Plants Iran   (Iran)

Author keywords

Adjunctive therapy; Negative symptoms; Schizophrenia; Sildenafil

Indexed keywords

HALOPERIDOL; OLANZAPINE; PLACEBO; RISPERIDONE; SILDENAFIL;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DECREASED APPETITE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; HUMAN; INCREASED APPETITE; MALE; MONOTHERAPY; NERVOUSNESS; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOMATOLOGY; TACHYCARDIA; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PURINES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULFONES; YOUNG ADULT;

EID: 79952487439     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-2044-z     Document Type: Article

References (28)

1. Abbasi SH, Behpournia H, Ghoreshi A, Salehi B, Raznahan M, Rezazadeh SA, Rezaei F, Akhondzadeh S (2010) The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res 116:101-106
2. Akhondzadeh S (1998) The glutamate hypothesis of schizophrenia. J Clin Pharm Ther 23:243-246
3. Akhondzadeh S (2001) The 5-HT hypothesis of schizophrenia. IDrugs 4:295-300
4. Akhondzadeh S (2006) Pharmacotherapy of schizophrenia: the past, present and future. Curr Drug Ther 1:1-7
5. Akhondzadeh S, Mohammadi MR, Amini-Nooshabadi H, Davari Ashtiani R (1999) Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. J Clin Pharm Ther 24:49-42
6. Akhondzadeh S, Rezaei F, Larijani B, Nejatisafa AA, Kashani L, Abbasi SH (2006) Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr Res 84:405-410
7. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B (2007) Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 90:179-185 (Pubitemid 46177578)
8. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. Fourth edition, text revision. American Psychiatric Association, Washington
9. Buchanan RW (2007) Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 33:1013-1022
10. Buckley PF, Stahl SM (2007) Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-desac? Acta Psychiatr Scand 115:93-100
11. Carlsson ML, Carlsson A, Nilsson M (2004) Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 11:267-277 (Pubitemid 38240207)
12. Chouinard G, Ross-Chouinard A, Annables L, Jones BD (1980) Extrapyramidal symptoms rating scale (abstract). Can J Neurol Sci 7:233
13. Coyle JT (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26:365-384
14. Erhart SM, Marder SR, Carpenter WT (2006) Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull 32:234-237
15. Goff DC, Cather C, Freudenreich O, Henderson DC, Evins AE, Culhane MA, Walsh JP (2009) A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacol 202:411-417
16. Gopalakrishnan R, Jacob KS, Kuruvilla A, Vasantharaj B, John JK (2006) Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. Am J Psychiatry 163:494-499 (Pubitemid 44469393)
17. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale for schizophrenia. Schizophr Bull 13:261-276 (Pubitemid 18039085)
18. Laruelle M, Kegeles LS, Abi-Dargham A (2003) Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann NY Acad Sci 1003:138-158 (Pubitemid 38083052)
19. Mohammadi MR, Akhondzadeh S (2001) Schizophrenia: etiology and pharmacotherapy. IDrugs 4:1167-1172
20. Möller HJ (2004) Non-neuroleptic approaches to treating negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci 254:108-116
21. Murphy BP, Chung YC, Park TW, McGorry PD (2006) Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 88:5-25 (Pubitemid 44693240)
22. Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, Amini-Nooshabadi H (1999) Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther 24:369-374 (Pubitemid 29520787)
23. Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J (2009) Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacol 202:419-443
24. Seeman P (2009) Glutamate and dopamine components in schizophrenia. J Psychiatry Neurosci 34:143-149
25. Siuciak JA (2008) The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 22:983-993
26. Stahl SM (2007) Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors. CNS Spectr 12:423-427
27. Ueoka Y, Tomotake M, Tanaka T, Kaneda Y, Taniguchi K, Nakataki M, Numata S, Tayoshi S, Yamauchi K, Sumitani S, Ohmori T, Ueno SI, Ohmori T (2010) Quality of life and cognitive dysfunction in people with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (in press)
28. Zhang HT (2010) Phosphodiesterase targets for cognitive dysfunction and schizophrenia - a New York Academy of Sciences meeting. IDrugs 13:166-168